Colorectal cancer chemoprevention: the potential of a selective approach

被引:0
作者
Ben-Amotz, Oded [1 ]
Arber, Nadir [1 ,2 ,3 ]
Kraus, Sarah [1 ,2 ,3 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Surg A, Tel Aviv, Israel
[2] Tel Aviv Univ, Integrated Canc Prevent Ctr, Tel Aviv Souraski Med Ctr, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
adematous polyposis coli gene; all-trans-retinyl acetate; chemoprevention; colorectal cancer; tumor necrosis factor-related apoptosis-inducing ligand; INDUCED APOPTOSIS; CYCLIN D1; CELLS; TRAIL; PREVENTION; ROFECOXIB; CELECOXIB; INDUCTION; RETINOIDS;
D O I
10.1586/ERA.10.139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is a leading cause of cancer death, and therefore demands special attention. Novel recent approaches for the chemoprevention of CRC focus on selective targeting of key pathways. We review the study by Zhang and colleagues, evaluating a selective approach targeting APC-deficient premalignant cells using retinoid-based therapy and TNF-related apoptosis-inducing ligand (TRAIL). This study demonstrates that induction of TRAIL-mediated death signaling contributes to the chemopreventive value of all-trans-retinyl acetate (RAc) by sensitizing premalignant adenoma cells for apoptosis without affecting normal cells. We discuss these important findings, raise few points that deserve consideration, and may further contribute to the development of RAc-based combination therapies with improved efficacy. The authors clearly demonstrate a synergistic interaction between TRAIL, RAc and APC, which leads to the specific cell death of premalignant target cells. The study adds to the growing body of literature related to CRC chemoprevention, and provides solid data supporting a potentially selective approach for preventing CRC using RAc and TRAIL.
引用
收藏
页码:1559 / 1562
页数:4
相关论文
共 20 条
[1]   Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL [J].
Altucci, L ;
Rossin, A ;
Raffelsberger, W ;
Reitmair, A ;
Chomienne, C ;
Gronemeyer, H .
NATURE MEDICINE, 2001, 7 (06) :680-686
[2]  
Altucci L, 2004, VITAM HORM, V67, P319
[3]   Chemoprevention of colorectal cancer: Ready for routine use? [J].
Arber, N ;
Levin, B .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (05) :517-525
[4]   Celecoxib for the prevention of colorectal adenomatous polyps [J].
Arber, Nadir ;
Eagle, Craig J. ;
Spicak, Julius ;
Racz, Istvan ;
Dite, Petr ;
Hajer, Jan ;
Zavoral, Miroslav ;
Lechuga, Maria J. ;
Gerletti, Paola ;
Tang, Jie ;
Rosenstein, Rebecca B. ;
Macdonald, Katie ;
Bhadra, Pritha ;
Fowler, Robert ;
Wittes, Janet ;
Zauber, Ann G. ;
Solomon, Scott D. ;
Levin, Bernard .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :885-895
[5]   A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas [J].
Baron, John A. ;
Sandler, Robert S. ;
Bresalier, Robert S. ;
Quan, Hui ;
Riddell, Robert ;
Lanas, Angel ;
Bolognese, James A. ;
Oxenius, Bettina ;
Horgan, Kevin ;
Loftus, Susan ;
Morton, Dion G. .
GASTROENTEROLOGY, 2006, 131 (06) :1674-1682
[6]   Celecoxib for the prevention of sporadic colorectal adenomas [J].
Bertagnolli, Monica M. ;
Eagle, Craig J. ;
Zauber, Ann G. ;
Redston, Mark ;
Solomon, Scott D. ;
Kim, KyungMann ;
Tang, Jie ;
Rosenstein, Rebecca B. ;
Wittes, Janet ;
Corle, Donald ;
Hess, Timothy M. ;
Woloj, G. Mabel ;
Boisserie, Frederic ;
Anderson, William F. ;
Viner, Jaye L. ;
Bagheri, Donya ;
Burn, John ;
Chung, Daniel C. ;
Dewar, Thomas ;
Foley, T. Raymond ;
Hoffman, Neville ;
Macrae, Finlay ;
Pruitt, Ronald E. ;
Saltzman, John R. ;
Salzberg, Bruce ;
Sylwestrowicz, Thomas ;
Gordon, Gary B. ;
Hawk, Ernest T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :873-884
[7]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[8]   Trail - At the center of drugable anti-tumor pathways [J].
Clarke, N ;
Nebbioso, A ;
Altucci, L ;
Gronemeyer, H .
CELL CYCLE, 2005, 4 (07) :914-918
[9]   Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL [J].
Clarke, N ;
Jimenez-Lara, AM ;
Voltz, E ;
Gronemeyer, H .
EMBO JOURNAL, 2004, 23 (15) :3051-3060
[10]   Retinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs [J].
Freemantle, Sarah J. ;
Guo, Yongli ;
Dmitrovsky, Ethan .
CANCER PREVENTION RESEARCH, 2009, 2 (01) :3-6